However, p53 deletion-induced non-small cell lung carcinoma (NSCLC) is sensitive to the disruption of BCAT1/2 because the high expression of BCAA catabolic enzymes leads to active use of BCAAs (Mayers et al., 2016). This evidence concerns the gene BCAT1 and non-small cell lung carcinoma.